Cel-Sci (NYSEAMERICAN:CVM) Posts Earnings Results

Cel-Sci (NYSEAMERICAN:CVM) issued its earnings results on Friday. The company reported ($0.67) earnings per share for the quarter, FiscalAI reports.

Cel-Sci Stock Up 10.0%

CVM traded up $0.13 during trading on Friday, reaching $1.43. 1,114,174 shares of the stock were exchanged, compared to its average volume of 700,046. The stock has a market cap of $12.14 million, a P/E ratio of -0.15 and a beta of 0.70. Cel-Sci has a twelve month low of $0.89 and a twelve month high of $13.48. The stock’s 50 day moving average price is $3.29 and its two-hundred day moving average price is $4.92. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.35 and a current ratio of 1.39.

Hedge Funds Weigh In On Cel-Sci

A number of institutional investors have recently added to or reduced their stakes in CVM. Bank of America Corp DE increased its holdings in Cel-Sci by 2,188.2% during the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after buying an additional 39,190 shares during the last quarter. Vanguard Group Inc. increased its holdings in Cel-Sci by 59.7% during the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after buying an additional 109,352 shares during the last quarter. MAI Capital Management increased its holdings in Cel-Sci by 18.4% during the third quarter. MAI Capital Management now owns 76,861 shares of the company’s stock worth $707,000 after buying an additional 11,928 shares during the last quarter. US Bancorp DE acquired a new position in Cel-Sci during the third quarter worth $80,000. Finally, HighTower Advisors LLC acquired a new position in Cel-Sci during the fourth quarter worth $53,000. 12.08% of the stock is currently owned by institutional investors and hedge funds.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.